NVO CLASS ACTION UPDATE: Novo Nordisk Investors are Reminded to Contact BFA Law before Imminent March 25 Deadline
Novo Nordisk is a healthcare company focused on the research, development, manufacturing, and distribution of pharmaceutical products globally. During the relevant period, Novo Nordisk was conducting ...
Genmab upgraded to Neutral from Underperform at Exane BNP Paribas
Exane BNP Paribas upgraded Genmab (GMAB) to Neutral from Underperform with a DKK 1,500 price target. The firm sees a “reasonable” valuation at ...
Genmab stock rating raised, price target cut by BNP Paribas Exane
Exane analyst Victor Floch upgraded Genmab (NASDAQ:GMAB) A/S shares from Underperform to Neutral, adjusting the price target ...